-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 23, the official website of NMPA showed that the application for the new indication of Sanofi Priyuumab has entered the administrative examination and approval stage, or it will be approved in the near future
Dupilumab is a human monoclonal antibody developed by Sanofi that targets IL-4Rα
In March 2017, Duplizumab was approved by the FDA to become the first targeted biologic drug for the treatment of moderate to severe atopic dermatitis in adults.
On June 17, 2020, Duplizumab was approved in China for the treatment of moderate to severe atopic dermatitis in adults
From the Insight database (http://db.
Atopic dermatitis is a common recurrent, chronic inflammatory skin disease.
According to the EvaluatePharma report, Dupixent will become a key driving force for Sanofi’s future growth.